Comparative Pharmacology
Head-to-head clinical analysis: HALFAN versus MEFLOQUINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALFAN versus MEFLOQUINE HYDROCHLORIDE.
HALFAN vs MEFLOQUINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HALFAN (halofantrine) is an antimalarial agent that acts as a blood schizonticide. It is thought to inhibit the polymerization of heme into hemozoin, leading to toxic accumulation of free heme within the parasite's food vacuole. It may also interfere with nucleic acid synthesis.
Mefloquine is a quinoline antimalarial agent that acts as a blood schizontocide. Its exact mechanism is unknown but is thought to involve forming toxic heme complexes or inhibiting heme polymerase, leading to parasite death.
Adults: 500 mg orally once daily.
250 mg (1 tablet) orally once weekly for prophylaxis; 1250 mg (5 tablets) as a single oral dose for treatment of uncomplicated malaria.
None Documented
None Documented
Terminal elimination half-life is 10-18 hours (mean 14 hours) in healthy adults, allowing twice-daily dosing.
~2-4 weeks (terminal half-life); clinical context: long half-life allows weekly dosing for prophylaxis, but accumulation can occur with repeated doses.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% unchanged drug; biliary/fecal elimination of metabolites approximately 20-30%.
~83% (fecal/biliary), ~9% (renal unchanged), ~2.5% (renal as metabolite).
Category C
Category A/B
Antimalarial
Antimalarial